Skip to main page content
U.S. flag

An official website of the United States government

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 May 25;20(5):1453-1456.
doi: 10.31557/APJCP.2019.20.5.1453.

Circulating miR-20a and miR-26a as Biomarkers in Prostate Cancer

Peyman Mohammadi Torbati  1 , Fatemeh Asadi  2 , Pezhman Fard-Esfahani  2
Affiliations

Circulating miR-20a and miR-26a as Biomarkers in Prostate Cancer

Peyman Mohammadi Torbati et al. Asian Pac J Cancer Prev. .

Abstract

Objective: Circulating microRNAs (miRNAs), present in body fluids, have been considering importance as cancer biomarkers. The primary aim of this study was to assess whether circulatory miR-20a and miR-26a can be used as diagnostic biomarkers in prostate cancer (PCa). Methods: Relative expression miR-20a and miR-26a has been assessed in 40 patients with PCa and 40 non-cancerous volunteer. Sample Collection of patients was performed before and one week after prostatectomy. Total RNA was extracted from serum and miR-20a and miR-26a expressions were quantified by using Real-Time PCR method. Results: miR-20a was significantly up-regulated in pre-operation serum samples of PCa patients compared to the serum samples of non-cancerous controls, however, in post-operation samples no significant differences was showed. miR-26a level was not significantly decreased in pre and post-operation serum samples compared to the serum samples of controls. However, the expression level ratios of both miR-20a and miR-26a were insignificantly decreased when post-operation serum samples compared to pre-operation ones. Conclusion: Decrement of circulating miR-20a and miR-26a in patients after surgery may reflect the tumoral origin of those microRNAs and the results may use for tumor remnant monitoring after prostatectomy.

Keywords: Prostate cancer; circulatory microRNAs; miR-20a; miR-26a.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Relative Expression of Circulating miR-20a and miR-26a. Post-O and Pre-O, post-operation and pre-operation serum samples, respectively; ns, non-significant; *, p-value < 0.05; **, p-value < 0.01; ***, p-value < 0.001.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Ambs S, Prueitt RL, Yi M, et al. Genomic profiling of microRNA and messenger RNA reveals deregulated microRNA expression in prostate cancer. Cancer Res. 2008;68:6162–70. - PMC - PubMed
    1. Backer H. Prostate cancer screening:exploring the debate. Permanente J. 1999;3:330–40.
    1. Brase JC, Johannes M, Schlomm T, et al. Circulating miRNAs are correlated with tumor progression in prostate cancer. Int J Cancer. 2011;128:608–16. - PubMed
    1. Bryant R, Pawlowski T, Catto J, et al. Changes in circulating microRNA levels associated with prostate cancer. Br J Cancer. 2012;106:768. - PMC - PubMed
    1. Deng M, Tang H-l, Lu X-h, et al. miR-26a suppresses tumor growth and metastasis by targeting FGF9 in gastric cancer. PLoS One. 2013;8:e72662. - PMC - PubMed